Post
Regeneron’s gene therapy triumphs twice, restoring hearing in children
Regeneron Pharmaceuticals’ gene therapy for otoferlin hearing loss, DB-OTO, has restored hearing to normal in an 11-month-old child within 24 …
Regenex Bio eyes FDA meeting to confirm pivotal DMD trial
Regenex Bio has announced it is meeting with the US Food and Drug Administration (FDA) with plans to initiate a …
Acepodia reports preliminary results from ACE1831 Phase I trial
Clinical-stage biotechnology company Acepodia has reported preliminary results from the Phase I study of anti-CD20 antibody conjugated allogeneic gamma delta …
Teva and Medincell report positive data for TEV-‘749 in schizophrenia trial
Teva and Medincell have announced positive results from the Phase III Subcutaneous OLAnzapine Extended-Release Injection Study (SOLARIS) trial’s efficacy portion …
NeuShen begins dosing for Phase I trial of schizophrenia treatment
NeuShen Therapeutics has dosed the first healthy volunteer in Australia, marking the start of a Phase I first-in-human clinical trial …
Phanes Therapeutics signs clinical supply agreement with Roche
US-based biopharmaceutical company Phanes Therapeutics has announced a clinical supply agreement with Roche for a combination therapy study. The collaboration will …
ESCMID 2024: Long-acting injectables for HIV prevention
At the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global (formerly ECCMID) conference in Barcelona, Spain, the …
UK report warns that economic instability is threatening life sciences sector
A report published by Medicines Discovery Catapult (MDC) is urging the UK life sciences sector to boost investment following findings …
Zenas raises $200m to advance autoimmune antibody therapy
US-based Zenas BioPharma has raised $200m in a Series C round to support the clinical development of its lead candidate, …
OCT Europe: Data governance guidance provides much-needed clarity
The introduction of a section dedicated to data governance in the European good clinical practice (GCP) guidance provides much-needed clarity. In …
Uproleselan’s failed Phase III AML trial shakes up GlycoMimetics’ future
On 6 May 2024, US-based biotech GlycoMimetics announced that its E-selectin inhibitor candidate uproleselan had failed to improve the overall …
Pfizer reports fatality in Phase II DMD gene therapy study
Pfizer has reported the death of a patient in the Phase II DAYLIGHT study of experimental gene therapy, fordadistrogene movaparvovec, …
Neurogene reports initial data from Rett syndrome gene therapy trial
Neurogene has shared initial safety and tolerability results from its ongoing Phase I/II clinical trial of NGN-401, a gene therapy …
RION doses first subject in Phase IIa diabetic foot ulcer therapy trial
Regenerative medicine company RION has dosed the first subject in the Phase IIa clinical trial of its purified exosome product …
LEO Pharma reports positive data from Phase III plaque psoriasis trial
LEO Pharma has announced positive data from the Phase III clinical trial of Enstilar (LEO 90100) in Chinese adult patients …